CLDN18.2 Moves From Scientific Observation to Biomarker-Driven Oncology
A decade ago, CLDN18.2 was a laboratory observation with uncertain clinical weight. Today, it sits among the most closely watched targets in gastrointestinal oncology, especially in gastric cancer, where biomarker-driven treatment decisions increasingly depend on finding the right patients early and interpreting expression data correctly.
The arc from discovery to practice has been unusually fast for a target that began as a membrane biology question. In healthy tissue, CLDN18.2 is largely hidden within the cell membrane, but in a substantial proportion of gastrointestinal tumors it becomes exposed on the tumor cell surface. That biological shift gave researchers a plausible therapeutic target and created the possibility of selective intervention in cancers that have historically been difficult to treat well.
The practical challenge arrived immediately after the biology made sense. A biomarker can be clinically relevant only if clinicians can test for it, interpret it consistently, and use the result in time to influence treatment selection.
Why Testing Logistics Became Part of the Science
The clinical development of CLDN18.2 has been about more than proving efficacy. It has also required building the infrastructure around the biomarker itself: pathology workflows, tissue access, timing of testing, and multidisciplinary coordination across diagnosis and treatment planning.
In gastric cancer, those steps matter because first-line decisions often have to be made quickly. Tissue may be limited, specimen handling varies, and biomarker information may not be available unless the testing pathway is embedded early in the care process. When expression levels differ from patient to patient, a simple positive-or-negative framework can miss the nuance that shapes real-world treatment decisions.
This is where biomarker-driven oncology becomes operational rather than theoretical. The value of the target depends on whether a clinician can identify the right patient at the first diagnosis, confirm the result with enough confidence to act on it, and then integrate that information into a sequence of therapies that may extend well beyond the initial regimen.
A Decade of Investment Around Gastric Cancer
Astellas entered the field early, acquiring Ganymed in 2016 and deepening its investment in CLDN18.2 research. That move reflected confidence not only in the biology but also in the therapeutic potential of targeting a protein that appears on the surface of malignant cells while remaining comparatively concealed in normal tissue.
Over time, that early hypothesis matured into a body of evidence and operational experience around biomarker-driven care. The company’s oncology development leadership framed the journey as one that has moved from scientific possibility to clinical reality, with the next phase centered on how the field can expand patient access and sharpen the tools used in everyday practice.
The shift is important because early success in a biomarker field often creates a second set of questions. Once a target is validated, the field has to determine how to find patients efficiently, how to standardize testing, and how to incorporate the biomarker into decision-making without slowing treatment initiation.
Patient Identification Has Become the Core Clinical Problem
One of the most consequential changes in the CLDN18.2 field is that patient identification is no longer a narrow technical step. It is now a clinical process that shapes who receives biomarker-informed care and when.
Expression varies across patients, and the timing of testing can determine whether the result arrives in time to affect therapy selection. Multidisciplinary coordination also matters because pathology, oncology, and treatment logistics must align for the biomarker to change practice. If the result comes late, the opportunity to use it in first-line care may be lost, even when the tumor is biologically eligible.
Real-world evidence will likely become increasingly important in this setting. Controlled development programs establish whether a target works under trial conditions, but routine care reveals how often tissue is available, whether testing is performed at the right moment, and how consistently clinicians can act on the result.
New Modalities Aim to Match Biology With Need
The CLDN18.2 field is now moving beyond a single therapeutic concept. Astellas is pursuing investigational bispecifics and antibody-drug conjugates in addition to its broader CLDN18.2 pipeline, with programs spanning early-stage research through Phase 3 development.
Different modalities may matter because different patients and disease states may not respond the same way to one class of therapy. A bispecific approach can engage immune or tumor pathways differently from an antibody-drug conjugate, which brings cytotoxic payload delivery into the equation. In solid tumors, especially across heterogeneous expression levels, the therapeutic question is not just whether the target exists, but how best to exploit it across disease settings and biomarker ranges.
This is where sequencing becomes more than an academic issue. If CLDN18.2-directed therapy is to sit alongside other lines of treatment, clinicians will need evidence that helps them understand when to use it, what to use before it, and how to monitor disease after exposure.
The Next Phase Will Be Defined by Implementation, Not Discovery Alone
CLDN18.2 has already crossed a major threshold: it is no longer only a hypothesis about tumor biology. It is part of an active clinical conversation about how biomarkers should shape treatment decisions in gastric cancer and potentially in other solid tumors as well.
The remaining work is less glamorous and more consequential at the bedside. Physicians need clear testing pathways. Pathologists need standardized interpretation. Health systems need the infrastructure to move biomarker data quickly enough to matter. Patients need therapies that can be delivered in a sequence that reflects both tumor biology and the practical realities of care.
The field still faces unresolved questions about disease monitoring, treatment sequencing, and how CLDN18.2-directed strategies should be deployed across expression levels and tumor types. Those questions will not be answered by biology alone. They will depend on the next wave of clinical data, real-world implementation experience, and the ability of biomarker programs to function inside everyday oncology practice rather than outside it.